NEW CLINICAL EVIDENCE: 17x Greater Therapeutic Dose-Response for Concussion Treatment
Robotic-Assisted Multimodal Neurorehab produces 17× greater therapeutic dose-response and more complete concussion recovery than standard of care alone. Persistent Post-Concussion Syndrome (PPCS) remains one of the most challenging conditions to treat using traditional neurorehabilitation methods. Standard therapies often fail to fully resolve vestibular, sensorimotor, and cognitive deficits—leading to prolonged recovery, functional limitations, and reduced quality of life. As an FDA-cleared, FDA-Designated Breakthrough Medical Device, GyroStim delivers multimodal, technology-assisted neurorehabilitation , GyroStim delivers technology-assisted multimodal neurorehabilitation that simultaneously engages vestibular, visual, motor, somatosensory, and cognitive systems—producing faster, more effective, and more complete recovery. Clinical results show dramatic improvements when GyroStim neurorehabilitation is added to standard...